- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02480010
A Study of Pertuzumab in Participants With Prostate Cancer
August 18, 2015 updated by: Hoffmann-La Roche
An Open Label, Phase II, Multicenter Study to Evaluate the Efficacy and Safety of a Recombinant Humanized Antibody to HER2 (Pertuzumab) Administered Every 3 Weeks to Patients With Hormone-Refractory Prostate Cancer Who Have Not Been Treated With Chemotherapy
This study will evaluate the efficacy and safety of intravenous (IV) pertuzumab in participants with hormone-refractory prostate cancer who have had no previous chemotherapy.
Participants will be enrolled in two stages, the first (Cohort A) at a lower 420-mg dose and the second (Cohort B) at a higher 1050-mg dose based upon observations in Cohort A. Up to 50 participants may enter either cohort, for a total enrollment between 46 and 73 participants across 9 study centers.
Study Overview
Study Type
Interventional
Enrollment (Actual)
68
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lyon, France, 69008
-
Montpellier, France, 34298
-
-
-
-
-
Berlin, Germany, 12203
-
-
-
-
-
Parma, Italy, 43100
-
Roma, Italy, 00152
-
-
-
-
-
Rotterdam, Netherlands, 3075 EA
-
-
-
-
-
Barcelona, Spain, 08035
-
Valencia, Spain, 46009
-
-
-
-
-
Cardiff, United Kingdom, CF14 2TL
-
Sutton, United Kingdom, SM2 5PT
-
Weston Super Mare, United Kingdom, BS23 4TQ
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Adults greater than (>) 18 years of age
- Histologically documented adenocarcinoma of the prostate resistant to hormone therapy, progressed at 4 to 6 weeks following anti-androgen withdrawal
- Prostate-specific antigen (PSA) values at least 20 ng/mL among those with asymptomatic or mildly symptomatic disease
- Karnofsky performance status (KPS) at least 80 percent (%)
- Castrate testosterone less than (<) 50 ng/dL
- Life expectancy at least 12 weeks
- Left ventricular ejection fraction (LVEF) at least 50%
- Adequate hematologic, hepatic, and renal function
Exclusion Criteria:
- Prior chemotherapy, radionucleotide therapy, or immunotherapy for prostate cancer
- Systemic corticosteroids within 1 month prior to Screening
- Bisphosphonates within 6 months, narcotic analgesics within 2 weeks, or any investigational agent with 28 days of study drug
- Prior cumulative doxorubicin dose of > 360 mg/m^2 or equivalent
- Central nervous system (CNS) or pulmonary metastases
- Other malignancies, except adequately treated basal or squamous cell skin cancer
- Significant cardiovascular disease
- Active/uncontrolled concurrent illness or infection
- Major surgery or traumatic injury within 4 weeks of study drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pertuzumab 1050 mg (Cohort B)
Participants in Cohort B will receive 1050 mg pertuzumab via IV infusion on Day 1 of each 3-week cycle.
At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment.
If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
|
Participants will receive pertuzumab on Day 1 of each 3-week cycle.
In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion.
In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
Other Names:
|
Experimental: Pertuzumab 420 mg (Cohort A)
Participants in Cohort A will receive an IV loading dose of 840 milligrams (mg) pertuzumab followed by 420 mg via IV infusion on Day 1 of each 3-week cycle.
At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment.
If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
|
Participants will receive pertuzumab on Day 1 of each 3-week cycle.
In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion.
In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Confirmed, Objective Response, Non-Response or Progressive Disease by PSA Levels Within the First 24 Weeks of Treatment With Pertuzumab
Time Frame: Screening, Every 3 weeks up to Week 24
|
Objective PSA response rate was determined according to Prostate Specific Antigen Working Group (PSAWG) guidelines.
All participants achieving a drop in PSA of greater than or equal to (≥) 50 percent (%) from baseline (confirmed with a second value at least 4 weeks later) fulfilled the criteria of a PSA response.
The confirmatory second value had to be at least 50% lower than baseline, but could be higher than the first drop in PSA.
Confirmatory value could not be 50% higher compared to first drop in PSA.
The date of response was the date the first 50% (or greater) decline was observed.
Progressive disease (PD) was defined by a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which documented progressively increasing values.
Non-response was defined as neither PD nor Response.
|
Screening, Every 3 weeks up to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Disease Progression
Time Frame: Screening, Every 3 weeks up to a maximum of 18 months
|
Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events.
1) PSA progression as defined by the PSAWG, 2) Evidence of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 3) One bone scan at least 6 months subsequent to baseline demonstrating 2 or more new skeletal lesions and 4) An event due to metastatic prostate cancer requiring intervention.
|
Screening, Every 3 weeks up to a maximum of 18 months
|
Percentage of Participants With Objective Response (Complete Response [CR] or Partial Response [PR]) by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
Time Frame: Screening, Weeks 6, 12, 24, 36 and 48
|
Overall objective response by RECIST criteria (CR or PR) was to be defined for participants who had measurable disease at baseline or developed new lesions post-baseline.
The longest diameter only for all target lesions was measured and the following responses recorded: CR: disappearance of all target lesions.
PR: at least a 30% decrease in the sum of the longest diameter as compared to the baseline sum longest diameter.
|
Screening, Weeks 6, 12, 24, 36 and 48
|
Time to Response
Time Frame: Screening, Every 3 weeks for a maximum of 18 months
|
Time to response was the date of the first documentation of PSA response.
|
Screening, Every 3 weeks for a maximum of 18 months
|
Duration of Response According to PSA Levels
Time Frame: Baseline, Every 3 weeks for a maximum of 18 months
|
Duration of PSA Response was measured from first 50% decline in PSA compared to baseline until the time at which there was an increase of ≥50% from the PSA nadir, provided the absolute increase was at least 5 nanograms per milliliter (ng/ml).
The increase must have been confirmed by a second consecutive measurement that was at least 50% above the nadir.
|
Baseline, Every 3 weeks for a maximum of 18 months
|
Duration of Response According to RECIST Criteria
Time Frame: Baseline, Weeks 6, 12, 24, 36 and 48
|
For participants with measurable disease, duration of response was defined as first documentation of tumor response, either a PR or CR, to first documentation of PD or death.
Participants who never progressed or died were censored at their last tumor measurement.
|
Baseline, Weeks 6, 12, 24, 36 and 48
|
Percentage of Participants Without Progression
Time Frame: Screening, Weeks 3, 6, 9 and 12
|
Disease progression was defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Non-progression included participants who had responded plus those who had not responded and not progressed within the first 3 cycles.
|
Screening, Weeks 3, 6, 9 and 12
|
Time to Prostate Cancer Pain Progression
Time Frame: Every 3 weeks up to a maximum of 18 weeks
|
Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events: 1) Opioid therapy, 2) Radiation therapy, 3) Glucocorticoid therapy, 4) Radionuclide therapy or 5) Chemotherapy.
|
Every 3 weeks up to a maximum of 18 weeks
|
Overall Survival
Time Frame: Screening, Every 3 weeks up to a maximum of 18 months
|
Overall survival was defined as the interval of time in weeks between start of treatment and day of death.
Participants who did not die while being followed were censored at the last time that they were known to be alive.
|
Screening, Every 3 weeks up to a maximum of 18 months
|
Time to Treatment Failure
Time Frame: Every 3 weeks up to a maximum of 18 weeks
|
Time to Treatment Failure was time to the first documentation of progressive disease, day of death while on study (or 30 days after withdrawing from the trial) or day of early discontinuation due to toxicity (adverse events or abnormal laboratory value), refusal of treatment/refusing to cooperate/withdrawing consent, insufficient therapeutic response, or failure to return, whichever is earliest, after the start of treatment.
Participants who did not experience any of the above events while on study were censored on the day of their last PSA or tumor measurement, whichever was later.
|
Every 3 weeks up to a maximum of 18 weeks
|
Change From Baseline in Bone Alkaline Phosphatase
Time Frame: Screening, Weeks 6, 12, 24, 36 and 48
|
Bone alkaline phosphatase (BAP) is the bone-specific isoform of alkaline phosphatase.
Serum Bone alkaline phosphatase is used to measure osteoporosis and is measured as units per liter (u/L).
|
Screening, Weeks 6, 12, 24, 36 and 48
|
Change From Baseline in N-Telopeptide
Time Frame: Screening, Weeks 6, 12, 24, 36 and 48
|
In bone physiology, the N-terminal telopeptide (or more formally, amino-terminal collagen crosslinks, and known by the acronym NTX) is a telopeptide that can be used as a biomarker to measure the rate of bone turnover.
NTX can be measured in the urine (uNTX) or serum (serum NTX).
|
Screening, Weeks 6, 12, 24, 36 and 48
|
Area Under the Concentration Curve Extrapolated to Infinity (AUC0-Inf) of Pertuzumab
Time Frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC).
The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug).
The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.
AUC is measured as micrograms times days per milliliter (µg*day/mL)
|
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
AUC to Last Measurable Concentration (AUC0-last) of Pertuzumab
Time Frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point.
The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.
|
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
Maximum Plasma Concentration of Pertuzumab
Time Frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
Cmax is the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose.
Cmax is measured as micrograms per mL (μg/mL).
|
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
Time to Maximum Plasma Concentration (Tmax) of Pertuzumab
Time Frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1 and on Days 8 and 15, Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
Cmax refers to the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose.
tmax is the time at which the Cmax is observed.
|
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1 and on Days 8 and 15, Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
Terminal Elimination Half-Life (t1/2) of Pertuzumab
Time Frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
t1/2 is the time in days required for the concentration of the drug to reach half of its original value
|
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
Serum Clearance of Pertuzumab
Time Frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body).
It is measured as milliliters per day (mL/day).
|
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
Volume of Distribution at Steady State of Pertuzumab
Time Frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma.
|
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
Mean Residence Time (MRT) of Pertuzumab
Time Frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
MRT is the average time that pertuzumab is present in the systemic circulation and is measured in days.
|
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2003
Primary Completion (Actual)
September 1, 2005
Study Completion (Actual)
September 1, 2005
Study Registration Dates
First Submitted
June 5, 2015
First Submitted That Met QC Criteria
June 23, 2015
First Posted (Estimate)
June 24, 2015
Study Record Updates
Last Update Posted (Estimate)
September 18, 2015
Last Update Submitted That Met QC Criteria
August 18, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BO17004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Pertuzumab
-
Shanghai Henlius BiotechCompletedHealthy Male VolunteersChina
-
Zydus Lifesciences LimitedNot yet recruiting
-
Shengjing HospitalNot yet recruiting
-
European Organisation for Research and Treatment...Hoffmann-La RocheCompletedElderly Metastatic Breast Cancer PopulationBelgium, Italy, Netherlands, France, Poland, United Kingdom, Portugal, Sweden
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
BiocadRecruitingBreast CancerRussian Federation
-
Ontario Clinical Oncology Group (OCOG)Terminated
-
BiocadActive, not recruiting
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)Completed